BCL2L1 and ovarian carcinoma: Bcl-xL is known to be involved in ovarian cancer chemoresistance [29], [30], and the current study provides further evidence that Bcl-xL expression is significantly enhanced in carboplatin-resistant ovarian cancer cells.